Government watchdog attacks FDA conflicts plan

The FDA's plan to reconsider conflict-of-interest rules governing its advisory-panel experts is drawing fire from the Project on Government Oversight, which argues that the regulations should not be loosened. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.